Metabolic Clearance Rate

• 

  Subject Areas on Research

  • A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. 
  • A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents. 
  • A new era in pharmacotherapy: the need to understand the principles of therapeutic drug monitoring. 
  • A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. 
  • A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. 
  • ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. 
  • Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. 
  • Anatomical and physiological basis for the allometric scaling of cisplatin clearance in dogs. 
  • Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance. 
  • Antifungal pharmacodynamics: review of the literature and clinical applications. 
  • Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. 
  • Bilateral native nephrectomy improves renal isograft function in rats. 
  • Brief Report: Frequency of Monitoring Kidney Function in HIV-Uninfected Persons Using Daily Oral Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis. 
  • Canine bombesin-like gastrin releasing peptides stimulate gastrin release and acid secretion in the dog. 
  • Carbohydrate recognition systems in amphibians: primitive alpha 2-macroglobulin receptors. 
  • Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin. 
  • Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. 
  • Cerebral blood flow values during cardiopulmonary bypass: relatively absolute or absolutely relative? 
  • Characterization of alpha 2-macroglobulin-plasmin complexes: complete subunit cleavage alters receptor recognition in vivo and in vitro. 
  • Characterization of liposomes containing iodine-125-labeled radiographic contrast agents. 
  • Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. 
  • Clearance and distribution of recombinant murine gamma-interferon in mice. 
  • Clearance from the anterior chamber of RBCs from human diabetics. 
  • Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. 
  • Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). 
  • Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. 
  • Critical care aspects of lung transplantation. 
  • Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass. 
  • Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. 
  • Differences in the metabolic response to exogenous homocysteine in juvenile and adult rabbits. 
  • Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. 
  • Differential effects of ethanol in adolescent and adult rats. 
  • Double-blind, randomized comparison of ondansetron and intraoperative propofol to prevent postoperative nausea and vomiting. 
  • Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review. 
  • Effect of Multi Drug Resistance Protein 4 (MRP4) Inhibition on the Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Normal and Rats with LPS-Induced Inflammation. 
  • Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). 
  • Effect of dietary fish oil supplementation on eicosanoid production by rat renal allografts. 
  • Efficacy, tolerability, and kinetics of lamotrigine in infants. 
  • Estimation of Body Fat Percentage for Clinical Pharmacokinetic Studies in Children. 
  • Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. 
  • Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. 
  • Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. 
  • Fluorescence imaging of blood-brain barrier disruption. 
  • Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. 
  • Genome-wide study of methotrexate clearance replicates SLCO1B1. 
  • Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? 
  • Hepatic receptor that specifically binds oligosaccharides containing fucosyl alpha1 leads to 3 N-acetylglucosamine linkages. 
  • High dose chemotherapy with autologous peripheral blood progenitor cell transplantation in an anephric child with multiply recurrent Wilms tumor. 
  • Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. 
  • Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. 
  • Ifosfamide enantiomers: pharmacokinetics in children. 
  • Impact of precontrast T10 relaxation times on dynamic contrast-enhanced MRI pharmacokinetic parameters: T10 mapping versus a fixed T10 reference value. 
  • In vitro binding and in vivo clearance of human alpha 2-macroglobulin after reaction with endoproteases from four different classes. 
  • In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors. 
  • In vivo metabolism of inter-alpha-trypsin inhibitor and its proteinase complexes: evidence for proteinase transfer to alpha 2-macroglobulin and alpha 1-proteinase inhibitor. 
  • In vivo metabolism of reversibly inhibited alpha-thrombin. 
  • In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. 
  • Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. 
  • Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. 
  • Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. 
  • Intraperitoneal cisplatin and regional hyperthermia for ovarian carcinoma. 
  • Intravascular coagulation--a source of possible error in carbon-clearance determinations. 
  • Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). 
  • Letrozole in the treatment of breast cancer. 
  • Liposomal amphotericin B: clinical experience and perspectives. 
  • Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent. 
  • Menstrual cycle variability in midazolam pharmacokinetics. 
  • Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. 
  • Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. 
  • Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. 
  • Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. 
  • Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy. 
  • Oxygen and Perfusion Kinetics in Response to Fractionated Radiation Therapy in FaDu Head and Neck Cancer Xenografts Are Related to Treatment Outcome. 
  • PET/CT mediastinal and liver FDG uptake: effects of biological and procedural factors. 
  • Paramagnetic polymerized liposomes as new recirculating MR contrast agents. 
  • Parathyroid lesions: characterization with dual-phase arterial and venous enhanced CT of the neck. 
  • Patterns of internal and external tetraethylammonium block in four homologous K+ channels. 
  • Peptide YY: metabolism and effect on pancreatic secretion in dogs. 
  • Persistence of long, thin chrysotile asbestos fibers in the lungs of rats. 
  • Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. 
  • Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. 
  • Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. 
  • Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. 
  • Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. 
  • Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. 
  • Pharmacokinetics of diaziquone after three different dosage regimens. 
  • Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. 
  • Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. 
  • Pharmacokinetics of oral triazolam in children. 
  • Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. 
  • Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. 
  • Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. 
  • Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. 
  • Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. 
  • Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. 
  • Physiologic role for enhanced renal thromboxane production in murine lupus nephritis. 
  • Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. 
  • Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. 
  • Population pharmacokinetics of NNZ-2566 in healthy subjects. 
  • Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. 
  • Population pharmacokinetics of fluconazole in young infants. 
  • Population pharmacokinetics of micafungin in neonates and young infants. 
  • Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. 
  • Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. 
  • Predictors of target organ damage in hypertensive blacks and whites. 
  • Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species. 
  • Pyridazinones as selective cyclooxygenase-2 inhibitors. 
  • Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. 
  • Quantitative dynamic contrast-enhanced MRI of pelvic and lumbar bone marrow: effect of age and marrow fat content on pharmacokinetic parameter values. 
  • Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. 
  • Reduced arsenic clearance and increased toxicity in aquaglyceroporin-9-null mice. 
  • Regional cerebral blood flow estimated by 133-xenon inhalation. 
  • Resonating to the music of ubiquitination. 
  • Respiratory physiology of house sparrows in relation to high-altitude flight. 
  • Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. 
  • Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood. 
  • Slow-release nanoparticle-encapsulated delivery system for laryngeal injection. 
  • Soluble alpha2-macroglobulin receptor is increased in endotracheal aspirates from infants and children after cardiopulmonary bypass. 
  • Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. 
  • Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. 
  • The binding of fucose-containing glycoproteins by hepatic lectins. Re-examination of the clearance from blood and the binding to membrane receptors and pure lectins. 
  • The clearance of a monoclonal anti-DNA antibody following administration of DNA in normal and autoimmune mice. 
  • The clearance of human fibrinogen fragments D1, D2, D3 and fibrin fragment D1 dimer in mice. 
  • The clearance of human fibrinogen fragments X and Y in mice: a process mediated by the fragment D receptor. 
  • The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. 
  • The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). 
  • Time course of carbamazepine autoinduction. The VA Cooperative Study No.118 Group. 
  • Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-D3) dilution in rats. 
  • Toxicity and pharmacokinetics of the antibiotic fumagillin in yearling rainbow trout (Salmo gairdneri). 
  • Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology